查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球子宮肌瘤市場-2022-2029
市場調查報告書
商品編碼
961510

全球子宮肌瘤市場-2022-2029

Global Myomectomy Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 190 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球子宮肌瘤市場的增長是由子宮肌瘤患病率上升以及對診斷和治療子宮疾病的需求不斷增加推動的。子宮肌瘤及相關疾病患者數量的增加，微創手術的增加，以及用於安全有效的子宮肌瘤切除術的技術先進設備的採用率不斷提高，預計將推動市場。我在這裡。

對子宮疾病診斷和治療的需求不斷增長推動市場增長

肌瘤是女性最常見的盆腔腫瘤，全球患病率為 21.4%。大約 20% 到 80% 的女性在 50 歲時會患上子宮肌瘤。子宮肌瘤在 40 多歲和 50 歲出頭的女性中很常見。大約 80% 的非裔美國女性會在 50 歲時患上子宮肌瘤。隨著女性年齡的增長，她們更容易出現荷爾蒙失調、子宮異常出血、月經不調等婦科問題。 2017 年發表的另一項研究包括大約 5,000 名患有子宮肌瘤的意大利女性，發現 95% 的手術包括 36-55 歲的女性。此外，由於並發症更少和住院時間更短，微創手術的使用增加也有望推動市場增長。技術進步，例如越來越多地使用機器人手術和腹腔鏡輔助手術來實現高質量和高效的治療，也可能有助於肌瘤手術市場的增長。

由於子宮肌瘤摘除術的增加，技術先進產品的推出有望推動市場增長。諸如腹腔鏡誘導和機器人輔助肌瘤摘除術等技術進步已證明非切口手術可用於治療肌瘤，且無副作用或副作用極小。與開腹手術相比，腹腔鏡子宮肌瘤摘除術出血少、並發症少、住院時間短、恢復正常生活快。因此，使用機器人進行子宮肌瘤摘除術具有優於傳統腹腔鏡手術（開放手術）的幾個優點，並且在生殖手術領域被廣泛接受和採用。

與子宮肌瘤相關的並發症阻礙市場增長

但是，子宮肌瘤摘除術與出血、感染、腸梗阻、粘連形成、腸/膀胱/輸卵管/輸尿管損傷、傷口感染和傷口脫離有關。由於症狀復發，大約 20% 到 25% 接受過子宮肌瘤切除術的人需要再次進行盆腔手術，通常是子宮切除術。肌瘤的複發很常見，尤其是在患有多發性肌瘤的患者中。單發肌瘤患者的複發率為27%，多發肌瘤患者的複發率為59%。接受肌瘤切除術的患者應在手術前告知這些風險，並了解可能無法進行肌瘤切除術。

COVID-19 影響分析

COVID-19 大流行對子宮肌瘤市場的影響是巨大的。隨著全球 COVID-19 病例數量激增，醫療保健服務將資源重新分配給患有 COVID-19 的患者。提供了大流行期間患者管理的指南和建議。因此，醫院優先考慮緊急護理，並推遲或推遲肌瘤切除術等選擇性手術，導致等待手術的患者等待時間較長。 2020 年 CovidSurg 合作研究估計，在 COVID-19 造成的為期 12 週的中斷高峰期間，約有 2800 萬例手術（包括 81.7% 的良性手術）將被推遲。隨著病情恢復正常，預計子宮肌瘤會逐漸恢復。

全球子宮肌瘤手術市場報告將提供對大約 40 多個市場數據表、45 多個數字和 190 頁的覆蓋範圍的訪問。

內容

第 1 章全球子宮肌瘤市場的研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章全球子宮肌瘤市場 - 市場定義和概述

第 3 章全球子宮切除術市場執行摘要

  • 按類型劃分的市場細分
  • 按產品劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章全球子宮肌瘤市場 - 市場動態

  • 市場影響因素
    • 驅動程序
      • 子宮疾病診治需求上升
      • 微創手術的興起
    • 約束因素
      • 與子宮肌瘤摘除術相關的並發症
    • 商機
    • 影響分析

第 5 章全球子宮肌瘤市場 - 行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析

第 6 章全球子宮肌瘤市場 - COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需產品
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章全球子宮肌瘤摘除市場 - 按類型

  • 腹腔鏡
  • 腹腔鏡
  • 宮腔鏡檢查
  • 機器人

第 8 章全球子宮肌瘤摘除市場-按產品

  • 腹腔鏡動力粉碎機
  • 腹腔鏡封口機
  • 諧音女
  • 其他

第 9 章全球子宮肌瘤市場 - 按最終用戶分類

  • 醫院和診所
  • 手術中心
  • 其他

第 10 章全球子宮肌瘤摘除市場 - 按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章全球子宮肌瘤市場 - 競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準

第 12 章全球子宮肌瘤市場 - 公司簡介

  • Medtronic PLC
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Stryker Corporation
  • ConMed Corporation
  • INSIGHTEC Ltd
  • CooperSurgical Inc.
  • Hologic Inc.
  • Intuitive Surgical Inc.
  • KARL STORZ SE & Co. KG
  • B Braun
  • Richard Wolf Medical Instruments

第 13 章全球子宮肌瘤摘除術市場-DataM

簡介目錄
Product Code: DMOT2667

Market Overview

The Global Myomectomy Market is expected to grow at a high CAGR of 9.1% during the forecasting period (2022-2029).

Myomectomy is a surgical procedure to remove uterine fibroids. These common non-cancerous growths in the uterus of women at their childbearing age, cause symptoms such as heavy bleeding during the menstrual cycle, increased menstrual cramping, pain in the pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy preserves the chances of women getting pregnant.

Market Dynamics

The global myomectomy market growth is driven by the rising prevalence of uterine fibroids and the growing demand for the diagnosis and treatment of uterine disorders. The increasing number of patients suffering from uterine fibroids and associated conditions, the growing number of less invasive procedures, and the rising adoption of technologically advanced devices for safe and effective myomectomy procedures are the major factors expected to drive the market.

The growing demand for diagnosis and treatment of uterine disorder will drive the market growth

Uterine fibroids are the most common pelvic tumors in women, occurring globally with a prevalence of 21.4%. About 20% to 80% of women develop fibroids by the time they reach age 50. Fibroids are common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50. The increasing female aging population is propelling the growth of the market as the elderly population is more susceptible to gynecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand for the global myomectomy market. Another research study published in 2017, which included approximately 5,000 Italian women with uterine fibroids, showed that 95% of the surgeries performed included women in the age group of 36-55 years. Additionally, a rise in the number of minimally invasive surgical procedures due to fewer complications and reduced hospital stay is anticipated to drive the growth of the market. Technological advancements, such as the rise in the number of robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment, may also contribute to the growth of the myomectomy market.

The launch of technologically advanced products due to the increasing number of myomectomy procedures for uterine fibroids is likely to boost the market growth. Technological advancements such as the introduction of laparoscopic or robotically assisted myomectomy procedures have shown incisionless surgery with no or minimal side effects for fibroids treatment. As compared to the open abdominal myomectomy surgery, with robotic myomectomy patient experience less blood loss with fewer complication rates, have a shorter hospital stay, and returns to normal activities more quickly. Thus, the use of robots for myomectomy surgery and their several advantages over conventional laparoscopy (open surgery), have been widely accepted and incorporated into the field of reproductive surgery.

The complications associated with myomectomy will hamper the growth of the market

However, myomectomy is associated with hemorrhage, infection, bowel obstruction, adhesion formation, damage to the bowel, bladder, fallopian tube, ureter, wound infection, and wound separation. About 20-25% of patients undergoing myomectomy require another pelvic operation, usually hysterectomy because of recurrence of symptoms. Recurrent myomas are common, especially in patients with multiple myomas. Patients with a solitary myoma have a 27% recurrence rate, and those with multiple myomas have a rate of 59%. Patients undergoing myomectomy should be counseled pre-operatively about these risks and must understand that myomectomy may not be possible.

COVID-19 Impact Analysis

The impact of the COVID-19 pandemic is significant on the myomectomy market. With the surge of COVID-19 cases across the world, healthcare services diverted their resources toward the patients suffering from COVID-19. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures, such as myomectomy surgery, leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated that around 28 million operations would be delayed during the peak 12-week disruption due to COVID-19, including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.

Segment Analysis

The abdominal segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The abdominal segment, also known as the open type, is considered the classic myomectomy surgery. This procedure is performed by making a small horizontal incision (or a vertical incision for a larger uterus) across the abdomen region of the body. With the rise in the number of patients with uterine fibroids, the demand for myomectomy procedures may also increase. Abdominal myomectomy is the highly performed and preferred type of treatment. A 2017 UK research study published on Gynecological Surgery, Springer Open, involving physician consultants, identifies that nearly 70% of them perform open myomectomy. The open type is preferred based on the size and location of fibroids. Hence, due to such activities across different countries, the number of procedures is expected to grow further over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global myomectomy market

North America dominates the market for myomectomy and is expected to show a similar trend over the forecast period, owing to the rising prevalence of uterine fibroid. A 2018 article published in the American Journal of Obstetrics and Gynecology shows that the prevalence of uterine fibroids was found to be 10% in the United States, with higher occurring rates observed for black women and other ethnic or racial groups. Additionally, according to the World Economic Outlook 2021 by IMF, real GDP is projected to grow by 6.4% in the United States and 5% in Canada. These factors, coupled with high reimbursement rates and government initiatives, contribute to North America occupying the largest share of the overall myomectomy market.

The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.

Also, the adoption of minimally invasive and effective alternatives to open surgeries and technological advancements in devices with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the growth of the myomectomy market in this region.

Competitive Landscape

The myomectomy market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Medtronic PLC, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc., Hologic Inc., Intuitive Surgical Inc., KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Myomectomy Market globally. For instance, in August 2020, Hologic Inc. announced the acquisition of Acessa Health Inc., a privately held company focused on minimally invasive therapies for fibroids. This acquisition is anticipated to strengthen Hologic's fibroid treatment product portfolio.

Medtronic plc

Overview:

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical-Surgical Portfolio, and Diabetes Operating Unit.

Product Portfolio:

Veriset Hemostatic Patch: The Veriset patch is designed to address the unmet need for a simple to use, fast, and highly effective hemostatic patch. Medtronic launched the Veriset patch. It is designed to help to achieve hemostasis quickly and consistently, in ~1 minute.

Why Purchase the Report?

Visualize the composition of the global myomectomy market segmentation by type, product, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global myomectomy market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global myomectomy market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global myomectomy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 190 pages.

Table of Contents

1. Global Myomectomy Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myomectomy Market -Market Definition and Overview

3. Global Myomectomy Market - Executive Summary

  • 3.1. Market Snippet By Type
  • 3.2. Market snippet By Product
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Myomectomy Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing demand for diagnosis and treatment of the uterine disorder
      • 4.1.1.2. Rise in Minimally Invasive Procedures
    • 4.1.2. Restraints:
      • 4.1.2.1. The complications associated with myomectomy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myomectomy Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Myomectomy Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Product
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. Global Myomectomy Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Laparoscopic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Abdominal
  • 7.4. Hysteroscopic
  • 7.5. Robotic

8. Global Myomectomy Market - By Product

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Laparoscopic Power Morcellators*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Laparoscopic Sealer
  • 8.4. Harmonic Scalpel
  • 8.5. Others

9. Global Myomectomy Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals & Clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Surgical Centers
  • 9.4. Other

10. Global Myomectomy Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Myomectomy Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Myomectomy Market - Company Profiles

  • 12.1. Medtronic PLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Stryker Corporation
  • 12.3. ConMed Corporation
  • 12.4. INSIGHTEC Ltd
  • 12.5. CooperSurgical Inc.
  • 12.6. Hologic Inc.
  • 12.7. Intuitive Surgical Inc.
  • 12.8. KARL STORZ SE & Co. KG
  • 12.9. B Braun
  • 12.10. Richard Wolf Medical Instruments

LIST NOT EXHAUSTIVE

13. Global Myomectomy Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us